Patients with germline RET variants are encouraged to avoid dopamine D2 agonists and beta-adrenergic antagonists until pheochromocytoma is sufficiently ruled out, as these agents may trigger adverse events (Eng, 1999). This evidence concerns the gene RET and pheochromocytoma.